An Integrated Approach on Diagnosis and Treatment of Cerebral Veins and Intracranial Dural Sinuses Thrombosis (CVT)

Dear Colleagues,

Cerebral veins and intracranial dural sinuses thrombosis (CVT) is a rare disease in the general population. At least one risk factor can be identified in about 85% of CVT patients. Screening for a thrombophilic state should be performed for cases who present a high pretest probability of severe thrombophilia. Two pathophysiological mechanisms determine their highly variable clinical spectrum: increase in venular and capillary pressure, and decrease in cerebrospinal fluid absorption.

The clinical spectrum of CVT is usually non-specific. Four major syndromes have been noted: intracranial hypertension, seizures, focal neurological signs, and encephalopathy. Cavernous sinus thrombosis is the only CVT that produces a characteristic clinical syndrome.

Non-enhanced computer tomography (NECT) of the head is the most frequently performed imaging technique in the emergency department. CVT diagnosis is confirmed with CT venography (CTV), directly detecting the venous clot as a filling defect, or magnetic resonance imaging (MRI)/MR venography (MR-V), which also realize a better description of parenchymal abnormalities.

Acute phase therapy for CVT focuses on anticoagulation, the management of seizures, increased intracranial pressure, and the prevention of cerebral herniation. The majority of patients have a complete or partial recovery; however, they have an increased incidence of venous thromboembolism. Clinical and imaging follow-ups 3 to 6 months after diagnosis are recommended to assess for recanalization.

This Special Issue of Life (IF = 3.2), Journal Rank: JCR - Q1 (Biology) includes the following topics: epidemiology, risk factors, pathophysiology, clinical presentation, laboratory testing, and the imaging of CVT. The treatment of CVT represents another important aspect: acute-phase therapy, management after the acute phase, and prognosis. We are pleased to invite you to submit a manuscript covering clinical research, as well as systematic reviews and meta-analyses.

Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue’s website.

Prof. Dr. Dragos Catalin Jianu
Prof. Dr. Dafin Fior Muresanu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.